Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep 2010 Jul;5(3):157-62
Date
05/07/2010Pubmed ID
20446122DOI
10.1007/s11899-010-0051-0Scopus ID
2-s2.0-77955980418 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Allogeneic hematopoietic cell transplantation is curative for patients with high-risk leukemia, but disease recurrence remains a major cause of treatment failure. New tools are now available to potentially identify patients with minimal residual disease who are at high risk for treatment failure. These improvements in disease detection allow for new opportunities to prevent relapse. The transplant course can be conceptualized into the pretransplant, peritransplant, and posttransplant periods. This article discusses the differing transplant interventions aimed at reducing relapse in each of these periods, focusing on new approaches that are currently being conceived or in early-stage clinical trials.
Author List
Verneris MR, Burke MJAuthor
Michael James Burke MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Cord Blood Stem Cell TransplantationHematopoietic Stem Cell Transplantation
Humans
Leukemia
Leukemia, Myeloid, Acute
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Transplantation, Homologous
